This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Australasian Kidney Trials Network | |
|---|---|
| Name | Australasian Kidney Trials Network |
| Abbreviation | AKTN |
| Formation | 1999 |
| Headquarters | Sydney, New South Wales |
| Region served | Australia, New Zealand |
Australasian Kidney Trials Network is a clinical trials network dedicated to improving outcomes in nephrology through randomized controlled trials and collaborative research. It connects clinicians, researchers, hospitals, universities, and patient groups across Australia and New Zealand to design, conduct, and disseminate multicenter trials in kidney disease. The network works with health services, ethical review bodies, funding agencies, and international partners to translate evidence into practice.
The Network operates at the intersection of tertiary hospitals such as Royal Prince Alfred Hospital, St Vincent's Hospital, Sydney, Auckland City Hospital, and Royal Brisbane and Women's Hospital with universities including University of Sydney, University of New South Wales, University of Auckland, Monash University, University of Melbourne, University of Otago, Griffith University, Macquarie University, University of Western Australia, University of Queensland, Curtin University, Deakin University, Flinders University, La Trobe University, University of Wollongong, James Cook University, Swinburne University of Technology, Charles Darwin University, University of Tasmania, Bond University, University of Newcastle, University of South Australia, Australian National University, Victoria University, University of Canberra, Australian Catholic University, and research institutes such as Garvan Institute of Medical Research, Lionel Murphy Medical Research Institute, Walter and Eliza Hall Institute of Medical Research, Baker Heart and Diabetes Institute, Peter MacCallum Cancer Centre, QIMR Berghofer Medical Research Institute, Murdoch Children's Research Institute, The George Institute for Global Health, Telethon Kids Institute, Medical Research Institute of New Zealand, South Australian Health and Medical Research Institute, Menzies School of Health Research, and Victorian Comprehensive Cancer Centre.
The Network was established at the turn of the 21st century with founding collaborators from centers like Royal North Shore Hospital, Princess Margaret Hospital, Perth, Princess Alexandra Hospital, and Christchurch Hospital and academic leaders affiliated to Sydney Medical School, Auckland Medical School, and Melbourne Medical School. Early development involved partnerships with professional bodies including Royal Australasian College of Physicians, Australian and New Zealand Society of Nephrology, Renal Society of Australasia, Australian Clinical Trials Alliance, New Zealand Ministry of Health, and funding agencies such as National Health and Medical Research Council and Health Research Council of New Zealand. The Network's growth paralleled international consortia like International Society of Nephrology, European Renal Association–European Dialysis and Transplant Association, American Society of Nephrology, Kidney Disease: Improving Global Outcomes, US National Institutes of Health, Medical Research Council (United Kingdom), Wellcome Trust, European Commission, Bill & Melinda Gates Foundation, Canadian Institutes of Health Research, and World Health Organization initiatives.
Governance includes advisory and steering committees populated by clinicians from institutions such as Royal Hobart Hospital, Gold Coast University Hospital, Fiona Stanley Hospital, Mater Hospital, Brisbane, John Hunter Hospital, St Vincent's Hospital, Melbourne, Calvary Hospital, Canberra, and academics from Flinders University, La Trobe University, and University of Newcastle. Funding sources have included grants from National Health and Medical Research Council, Health Research Council of New Zealand, philanthropic organizations like The Ian Potter Foundation, The Myer Foundation, corporate sponsors, and partnerships with pharmaceutical companies such as Roche, Novartis, Bayer, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Amgen, Takeda, Bristol Myers Squibb, Eli Lilly and Company, AbbVie, Merck & Co., Johnson & Johnson, Novo Nordisk, Celgene, Biogen, Gilead Sciences, Regeneron Pharmaceuticals, Sandoz, Chiesi Farmaceutici, and device manufacturers like Baxter International, Fresenius Medical Care, Medtronic, GE Healthcare, Siemens Healthineers, Philips Healthcare, Boston Scientific, Abbott Laboratories, Terumo, B. Braun Melsungen AG, Cook Medical, Edwards Lifesciences, and ResMed.
The Network's trials span acute kidney injury, chronic kidney disease, dialysis modalities, transplantation, hypertension, glomerulonephritis, and metabolic complications, engaging specialties linked to Royal Perth Hospital, Liverpool Hospital, St George Hospital, Sydney, Box Hill Hospital, Royal Adelaide Hospital, Princess Royal Hospital, Adelaide, Taranaki Base Hospital, Whangarei Hospital, Middlemore Hospital, Christchurch Hospital, Dunedin Hospital, Hutt Valley Hospital, Wellington Regional Hospital, Mater Misericordiae Hospital, Brisbane, and community clinics associated with Nepean Hospital. Key trial types include randomized controlled trials influenced by methodologies from CONSORT, SPIRIT, ICMJE, Good Clinical Practice (GCP), Cochrane Collaboration, PRISMA systematic reviews, and statistical approaches found in work by Bradford Hill, Fisher, Neyman–Pearson, Cox, Kaplan–Meier, and Cox proportional hazards model.
Methodological rigor is supported by data coordination with biostatistics groups at University of Sydney School of Public Health, University of Auckland School of Population Health, University of Melbourne School of Population and Global Health, Monash Biostatistics Centre, Flinders Centre for Epidemiology and Biostatistics, and collaborations with international trialists from Oxford University, Cambridge University, Harvard Medical School, Yale School of Medicine, Johns Hopkins University, Stanford University School of Medicine, Massachusetts General Hospital, Brigham and Women's Hospital, Uppsala University, Karolinska Institutet, Université Paris Cité, Imperial College London, King's College London, University College London, McMaster University, University of Toronto, University of British Columbia, McGill University, University of Edinburgh, University of Glasgow, Leiden University Medical Center, Erasmus University Medical Center, KU Leuven, Ghent University Hospital, Universität Heidelberg, Charité – Universitätsmedizin Berlin, University of Tokyo, Seoul National University Hospital, National University of Singapore, Duke University School of Medicine, University of California, San Francisco, University of California, Los Angeles, Children's Hospital of Philadelphia, Vanderbilt University Medical Center, Mayo Clinic, Cleveland Clinic, Fred Hutchinson Cancer Research Center, Scripps Research, The Rockefeller University, Weill Cornell Medicine, and trial networks like European Organisation for Research and Treatment of Cancer, NIHR Clinical Research Network, Canadian Kidney Knowledge Translation and Generation Network, UK RENAL Research Network, and Nephrology Trials Network.
The Network has contributed to practice-changing evidence influencing dialysis prescriptions, fluid management in Intensive Care Units, anemia management, immunosuppression regimens in transplantation, and cardiovascular risk reduction in kidney disease, cited alongside landmark studies from HEMO Study, FREEDOM Study, SHARP, CREDENCE, DAPA-CKD, CANTOS, SAVOR-TIMI 53, EMPA-REG OUTCOME, LEADER, ADVANCE, AFFIRM-AHF, ATN Study, RENAL Study, VA NEPHRON-D Trial, IDEAL study, FREEDOM-CVO, COAPT Trial, STICH Trial, EVEREST Trial, SOLVD Trial, RALES Trial, PARADIGM-HF, RAAS blockade trials, SPRINT Trial, ACCORD Trial, ALLHAT Trial, and guidelines from KDIGO and National Institute for Health and Care Excellence.
Capacity building includes investigator-initiated trial workshops with professional societies like Australian and New Zealand Intensive Care Society, Cardiac Society of Australia and New Zealand, Australian Diabetes Society, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Royal Australasian College of Surgeons, Royal Australasian College of General Practitioners, Australian College of Nursing, New Zealand Nurses Organisation, Australian Clinical Trials Alliance, Australasian Epidemiological Association, Society for Clinical Trials, and training links to academic programs at Harvard T.H. Chan School of Public Health, London School of Hygiene & Tropical Medicine, Johns Hopkins Bloomberg School of Public Health, Columbia University Mailman School of Public Health, Yale School of Public Health, Melbourne School of Population and Global Health, Sydney School of Public Health, and professional development with Australian Commission on Safety and Quality in Health Care, Health Quality & Safety Commission (New Zealand), Therapeutic Goods Administration, Medicines and Healthcare products Regulatory Agency, and trial infrastructure from ClinicalTrials.gov, ANZCTR, EU Clinical Trials Register, ISRCTN registry, and ethics frameworks used by Human Research Ethics Committees.
Category:Nephrology research